Lymphocytes in atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 2, 2015, Pages 253-257

  Hedrick, Catherine C ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

aneurysm; atherosclerosis; B lymphocytes; Killer cells, natural; natural killer T cells; T cells regulatory; T lymphocytes

Indexed keywords

CD19 ANTIGEN; CD1D ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 5; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; AUTACOID;

ADIPOSE TISSUE; ANEURYSM; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; FOAM CELL; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; INSULIN RESISTANCE; LYMPHOCYTE HOMING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; NATURAL KILLER T CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; VASCULAR DISEASE; ANIMAL; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ATHEROSCLEROSIS; B-LYMPHOCYTE SUBSETS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; NATURAL KILLER T-CELLS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84921995072     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.305144     Document Type: Article

References (80)

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
2. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297.
3. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007;147:149-155.
4. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, Jacobs DR Jr, Wu C, Saad MF, Szklo M. Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2007;30:2951-2956. doi: 10.2337/dc07-1042.
5. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-2038.
6. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120-126.
7. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes. 1995;44:369-374.
8. Gleissner CA, Galkina E, Nadler JL, Ley K. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech. 2007;4:131-140. doi: 10.1016/j.ddmec.2007.12.005.
9. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131-138.
10. Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis. 1988;72:135-141.
11. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169-175.
12. Hansson GK. Atherosclerosis-an immune disease: The Anitschkov Lecture 2007. Atherosclerosis. 2009;202:2-10. doi: 10.1016/j. atherosclerosis.2008.08.039.
13. Hansson GK. Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci. 2001;947:157-165; discussion 165.
14. Tobias P, Curtiss LK. Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res. 2005;46:404-411. doi: 10.1194/jlr. R400015-JLR200.
15. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:1011-1016.
16. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2003;108:1232-1237. doi: 10.1161/01.CIR.0000089083.61317.A1.
17. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178-180. doi: 10.1038/nm1343.
18. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigenspecific immune responses. Proc Natl Acad Sci U S A. 2005;102:1596-1601. doi: 10.1073/pnas.0409015102.
19. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation. 2006;114:2047-2055. doi: 10.1161/ CIRCULATIONAHA.106.633263.
20. Gotsman I, Gupta R, Lichtman AH. The influence of the regulatory T lymphocytes on atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2493-2495. doi: 10.1161/ATVBAHA.107.153064.
21. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064-1071.
22. Schiller NK, Boisvert WA, Curtiss LK. Inflammation in atherosclerosis: lesion formation in LDL receptor-deficient mice with perforin and Lyst(beige) mutations. Arterioscler Thromb Vasc Biol. 2002;22:1341-1346.
23. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134:33-46. doi: 10.1016/j.clim.2009.07.002.
24. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-3897.
25. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol. 1996;149:675-685.
26. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
27. Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:864-870. doi: 10.1161/01.ATV.0000206122.61591.ff.
28. Zhou X. CD4+ T cells in atherosclerosis. Biomed Pharmacother. 2003;57:287-291.
29. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation. 2001;103:2610-2616.
30. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-43.
31. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun. 2010;2:325-333. doi: 10.1159/000314626.
32. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Böckler D, Katus HA, Dengler TJ. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009;183:8167-8175. doi: 10.4049/jimmunol.0901126.
33. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121:1746-1755. doi: 10.1161/ CIRCULATIONAHA.109.924886.
34. Taleb S, Tedgui A, Mallat Z. Interleukin-17: friend or foe in atherosclerosis? Curr Opin Lipidol. 2010;21:404-408. doi: 10.1097/ MOL.0b013e32833dc7f9.
35. Taleb S, Tedgui A, Mallat Z. Il-17 and th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015;35:258-264.
36. van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009;388:261-265. doi: 10.1016/j. bbrc.2009.07.152.
37. Entin-Meer M, Afek A, George J. Regulatory T-cells, FoxP3 and atherosclerosis. Adv Exp Med Biol. 2009;665:106-114.
38. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med. 2008;263:489-499. doi: 10.1111/j.1365-2796.2008.01944.x.
39. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation. 2013;127:1028-1039. doi: 10.1161/ CIRCULATIONAHA.112.001347.
40. Zhou J, Dimayuga PC, Zhao X, Yano J, Lio WM, Trinidad P, Honjo T, Cercek B, Shah PK, Chyu KY. CD8(+)CD25(+) T cells reduce atherosclerosis in apoE(-/-) mice. Biochem Biophys Res Commun. 2014;443:864-870. doi: 10.1016/j.bbrc.2013.12.057.
41. Li J, Ley K. Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2015;35:40-49. doi: 10.1161/ATVBAHA.114.303227.
42. Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124:185-195. doi: 10.1161/ CIRCULATIONAHA.110.006411.
43. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, Bharadwaj M, Walzem R, Chan L, Oka K, Thomas MJ, Sorci-Thomas MG. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009;29:843-849. doi: 10.1161/ATVBAHA.108.183442.
44. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008;134:97-111. doi: 10.1016/j.cell.2008.04.052.
45. Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation. J Immunol. 2010;184:173-183. doi: 10.4049/ jimmunol.0902372.
46. Ait-Oufella H, Wang Y, Herbin O, Bourcier S, Potteaux S, Joffre J, Loyer X, Ponnuswamy P, Esposito B, Dalloz M, Laurans L, Tedgui A, Mallat Z. Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. Arterioscler Thromb Vasc Biol. 2013;33:2374-2379. doi: 10.1161/ATVBAHA.113.301280.
47. McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Zhang H, Hui Yen Chng M, Engleman E. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34:2637-2643. doi: 10.1161/ATVBAHA.114.304636.
48. Rocha VZ, Folco EJ, Ozdemir C, Sheikine Y, Christen T, Sukhova GK, Tang EH, Bittencourt MS, Santos RD, Luster AD, Cohen DE, Libby P. CXCR3 controls T-cell accumulation in fat inflammation. Arterioscler Thromb Vasc Biol. 2014;34:1374-1381. doi: 10.1161/ATVBAHA.113.303133.
49. Jiang E, Perrard XD, Yang D, Khan IM, Perrard JL, Smith CW, Ballantyne CM, Wu H. Essential role of CD11a in CD8+ T-cell accumulation and activation in adipose tissue. Arterioscler Thromb Vasc Biol. 2014;34:34-45 doi: 10.1161/ATVBAHA.113.302077.
50. Ellison S, Gabunia K, Kelemen SE, England RN, Scalia R, Richards JM, Orr AW, Orr W, Traylor JG Jr, Rogers T, Cornwell W, Berglund LM, Goncalves I, Gomez MF, Autieri MV. Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler Thromb Vasc Biol. 2013;33:2316-2324. doi: 10.1161/ATVBAHA.113.301521.
51. Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot I, Kuiper J, van Puijvelde GH. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:2558-2565. doi: 10.1161/ATVBAHA.113.301879.
52. Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M, Hedblad B, Nilsson J, Björkbacka H. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler Thromb Vasc Biol. 2013;33:637-644. doi: 10.1161/ATVBAHA.112.300871.
53. Liu A, Ming JY, Fiskesund R, Ninio E, Karabina SA, Bergmark C, Frostegård AG, Frostegård J. Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins. Arterioscler Thromb Vasc Biol. 2015;35:197-205. doi: 10.1161/ ATVBAHA.114.304342.
54. Koulis C, Chen YC, Hausding C, Ahrens I, Kyaw TS, Tay C, Allen T, Jandeleit-Dahm K, Sweet MJ, Akira S, Bobik A, Peter K, Agrotis A. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2014;34:516-525. doi: 10.1161/ATVBAHA.113.302407.
55. Vanderlaan PA, Reardon CA. Thematic review series: the immune system and atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res. 2005;46:829-838. doi: 10.1194/jlr.R500003-JLR200.
56. Cheng HY, Wu R, Hedrick CC. Gammadelta (γδ) T lymphocytes do not impact the development of early atherosclerosis. Atherosclerosis. 2014;234:265-269. doi: 10.1016/j.atherosclerosis.2014.03.007.
57. Aslanian AM, Chapman HA, Charo IF. Transient role for CD1drestricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2005;25:628-632. doi: 10.1161/01. ATV.0000153046.59370.13.
58. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res. 2006;34:49-66.
59. Major AS, Wilson MT, McCaleb JL, Ru Su Y, Stanic AK, Joyce S, Van Kaer L, Fazio S, Linton MF. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24:2351-2357. doi: 10.1161/01.ATV.0000147112.84168.87.
60. Nakai Y, Iwabuchi K, Fujii S, et al. Natural killer T cells accelerate atherogenesis in mice. Blood. 2004;104:2051-2059. doi: 10.1182/ blood-2003-10-3485.
61. Rogers L, Burchat S, Gage J, Hasu M, Thabet M, Willcox L, Wilcox L, Ramsamy TA, Whitman SC. Deficiency of invariant V alpha 14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. Cardiovasc Res. 2008;78:167-174. doi: 10.1093/cvr/cvn005.
62. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med. 2004;199:417-422. doi: 10.1084/jem.20030997.
63. van Puijvelde GH, van Wanrooij EJ, Hauer AD, de Vos P, van Berkel TJ, Kuiper J. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb Haemost. 2009;102:223-230. doi: 10.1160/ TH09-01-0020.
64. VanderLaan PA, Reardon CA, Sagiv Y, Blachowicz L, Lukens J, Nissenbaum M, Wang CR, Getz GS. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol. 2007;170:1100-1107. doi: 10.2353/ajpath.2007.060188.
65. Li YS, Meng XY, Zhou Y, Zhang YY, Meng XM, Yang L, Hu P, Lu SY, Ren HL, Liu ZS, Wang XR. Magnetic bead and gold nanoparticle probes based immunoassay for β-casein detection in bovine milk samples. Biosens Bioelectron. 2014;66C:559-564. doi: 10.1016/j.bios.2014.12.025.
66. Bondarenko S, Catapano AL, Norata GD. The CD1d-natural killer T cell axis in atherosclerosis. J Innate Immun. 2014;6:3-12. doi: 10.1159/000351034.
67. Strodthoff D, Lundberg AM, Agardh HE, Ketelhuth DF, Paulsson-Berne G, Arner P, Hansson GK, Gerdes N. Lack of invariant natural killer T cells affects lipid metabolism in adipose tissue of diet-induced obese mice. Arterioscler Thromb Vasc Biol. 2013;33:1189-1196. doi: 10.1161/ ATVBAHA.112.301105.
68. Martin-Murphy BV, You Q, Wang H, De La Houssaye BA, Reilly TP, Friedman JE, Ju C. Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding. PLoS One. 2014;9:e80949. doi: 10.1371/journal.pone.0080949.
69. Selathurai A, Deswaerte V, Kanellakis P, Tipping P, Toh BH, Bobik A, Kyaw T. Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms. Cardiovasc Res. 2014;102:128-137. doi: 10.1093/cvr/cvu016.
70. Martínez-Rodríguez JE, Munné-Collado J, Rasal R, Cuadrado E, Roig L, Ois A, Muntasell A, Baro T, Alameda F, Roquer J, López-Botet M. Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus. Arterioscler Thromb Vasc Biol. 2013;33:2653-2659. doi: 10.1161/ATVBAHA.113.302163.
71. Kossmann S, Schwenk M, Hausding M, et al. Angiotensin II-induced vascular dysfunction depends on interferon-γ-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler Thromb Vasc Biol. 2013;33:1313-1319. doi: 10.1161/ ATVBAHA.113.301437.
72. Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting b cells in atherosclerosis: Closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol. 2014
73. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002;109:745-753. doi: 10.1172/JCI7272.
74. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vré E, Esposito B, Vilar J, Sirvent J, Van Snick J, Tedgui A, Tedder TF, Mallat Z. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207:1579-1587. doi: 10.1084/ jem.20100155.
75. Doran AC, Lipinski MJ, Oldham SN, et al. B-cell aortic homing and atheroprotection depend on Id3. Circ Res. 2012;110:e1-12. doi: 10.1161/ CIRCRESAHA.111.256438.
76. Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, Toh BH. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol. 2010;185:4410-4419. doi: 10.4049/jimmunol.1000033.
77. Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, Harmon DB, Tsimikas S, Witztum JL, Bender TP, McNamara CA. Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol. 2013;33:2771-2779. doi: 10.1161/ATVBAHA.113.302571.
78. Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier A, Binder CJ, Witztum JL. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med. 2008;263:479-488. doi: 10.1111/j.1365-2796.2008.01968.x.
79. Mantani PT, Ljungcrantz I, Andersson L, Alm R, Hedblad B, Björkbacka H, Nilsson J, Fredrikson GN. Circulating CD40+ and CD86+ B cell subsets demonstrate opposing associations with risk of stroke. Arterioscler Thromb Vasc Biol. 2014;34:211-218. doi: 10.1161/ATVBAHA.113.302667.
80. Karper JC, de Jager SC, Ewing MM, de Vries MR, Bot I, van Santbrink PJ, Redeker A, Mallat Z, Binder CJ, Arens R, Jukema JW, Kuiper J, Quax PH. An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation. Arterioscler Thromb Vasc Biol. 2013;33:2810-2817. doi: 10.1161/ ATVBAHA.113.301882.